Drug Discovery Tools for High-Content Analysis

Published by: Trimark Publications

Published: Jul. 13, 2007 - 108 Pages

Table of Contents

1. Overview

1.1 Objectives of the Report

1.2 Methodology

1.3 Scope of the Report

1.4 Executive Summary

2. Technologies and Product Offering for HCA

2.1 Definition of HCA and Why it is so Attractive a Discipline

2.2 Classes of Measurements Possible with HCA Approaches and Biologies Interrogated

2.3 Instrumentation Platforms for HCA

2.4 Reagent and Assay Platforms for HCA

2.5 Cell-based Screening Technologies in Drug Development

2.5.1 Applications of Cell-based Assays

2.5.2 Pharma Drug Discovery Paradigm and Compound Screening

2.5.3 HCA in the Biopharmaceutical Industry

3. Market Analysis of the High-Content Tools Space

3.1 HCA Market Size and Growth

3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the HCA Space

3.3 Experimental and Research Trends in HCA

3.4 Challenges and Market Drivers in HCA

3.4.1 Barriers to HCA

3.4.2 Drivers of HCA

3.5 HCA in Combination with RNAi

3.6 Market Landscape of Instrumentation for HCA

3.7 Reagents and Assays Usage in HCA

3.8 Trends in HCA Assays/Reagents Space—Major Product Vendors

3.9 Emerging Market Trends in HCA

3.10 Market Forecasts for the HCA Space

3.11 Use of HCS in Pharmaceutical Companies

3.12 Qualitative Opportunities and Challenges for Market Adoption

4. Strategic Analysis of the High-Content Tools Space

4.1 HCA Market Structure

4.2 Description of the Drug Discovery Marketplace and Definition of the Field

4.3 Key Market Drivers and Challenges in the HCA Space

4.4 Consolidated Picture of the HCA Marketplace

4.5 HCA Market Sectors and Growth Rate

4.6 Vendors of HCA Technology

5. HCA Technology Platforms

5.1 Methods of Digital Imaging

5.2 Fluorescence Microscopy

5.3 Major HCA Instrumentation

5.4 HCA Reagents

5.5 Imaging Software

5.6 Image Analysis Algorithms

5.7 Use of RNAi in HCA

5.8 Industry Alliance to Leverage RNAi and HCA

5.9 Emerging Trends in HCA Technology Platforms

6. HCA in Drug Selection and Screening

6.1 Stem Cells Used as a Drug Discovery Tool

6.2 Drug Discovery Companies Marketing Cell-based Assays

7. Company Profiles and Glossary of Terms in HCA

7.1 Acumen Pharmaceuticals, Inc.

7.2 Applied Biosystems

7.3 Becton, Dickinson and Company

7.4 Beckman Coulter, Inc.

7.5 Blueshift Biotechnologies, Inc.

7.6 Caden Biosciences, Inc.

7.7 Cellomics, Inc.

7.8 Cellumen, Inc.

7.9 Cenix BioScience

7.10 Cyntellect

7.11 Definiens

7.12 DiscoveRx

7.13 Euroscreen

7.14 Evotec Technologies

7.15 Fisher BioImage

7.16 General Electric

7.17 Guava Technologies, Inc.

7.18 Millipore

7.19 Molecular Devices Corporation

7.20 NIH Chemical Genomics Center

7.21 PerkinElmer

7.22 Spotfire

7.23 Translational Genomics Research Institute

7.24 Vala Sciences, Inc.

8. Glossary of Terms in the HCA Space

LIST OF FIGURES

Figure 2.1: Scope of Biological Parameters Addressed via a Typical HCA Experiment

Figure 2.2: Classes of Assays in Life Science Research and Drug Discovery Illustrating the Relationship between Cell-based Assays and HCA

Figure 2.3: New Paradigm of Drug Discovery and Development Illustrating the Central and Essential Role of Screening

Figure 2.4: Cumulative and New Drug Targets

Figure 3.1: Breakout of Market Survey Respondents by Geographical Location

Figure 3.2: Breakout of Market Survey Respondents by Affiliation—Academic, Commercial, Vendor

Figure 3.3: Segmentation of Respondent Pool based upon Usage of HCA in its Research Activities

Figure 3.4: Segmentation of the Survey Respondent Pool based upon the Length of Time they have been Using HCA in their Research Activities

Figure 3.5: Number of Parameters Studied Simultaneously in HCA Assays—Multivariate [Multi-Parameter] Analyses

Figure 3.6: Key Biological Processes Studied Utilizing HCA Tools

Figure 3.7: Breakout of HCA Assays Currently Performed or Expected to be Performed in the Future by Biological Pathway (or Target)

Figure 3.8: Breakout of HCA Experiments Performed Per Week (Distributed in our Respondent Pool) Across the Various Biological Pathways (and Targets)

Figure 3.9: Which of the Biologies (Pathways/Targets) Addressed Using HCA-based Approaches are Growing in Importance or Declining?

Figure 3.10: In Which Environment are HCA Assays Performed—Primary Screen, Secondary Screen, ADME/Tox Screen?

Figure 3.11: Key Challenges Faced by the Research Community in Their Practice of HCA

Figure 3.12: Various Drivers that are Leading the Research Community to Perform HCA

Figure 3.13: HCA Together with RNAi—Current and Future Experimental Formats

Figure 3.14: HCA Together with RNAi—Number of Experiments Performed Per Month by the Survey Respondent Pool

Figure 3.15: Growing and Steady Usage of the Various Formats where RNAi is coupled with HCA

Figure 3.16: Penetration of the Different HCA Instrumentation Platforms into the Marketplace

Figure 3.17: Instrumentation Platforms for HCA Ranked by Top Choice and Second Tier

Figure 3.18: HCA Instrumentation and where they lie on the Throughput Curve

Figure 3.19: Top Instrumentation Value Drivers in the HCA Space

Figure 3.20: Important Sub-Cellular Features Studied via HCA Approaches

Figure 3.21: Breakout of End-Point versus Kinetic Assays in the HCA Space

Figure 3.22: Types of Cellular Targets Studied Using HCA Approaches

Figure 3.23: Top-most Target Class Being Studied Utilizing HCA Approaches

Figure 3.24: Distribution of HCA Experiments across the Respondent Pool—Number of Experiments Performed Per Week

Figure 3.25: Average Reagent/Assay Costs Per HCA Experiment

Figure 3.26: Stratification of Reagent/Assay Suppliers into the HCA Space

Figure 3.27: Monthly Reagent/Assay Purchases for HCA by the End-User Community from the Various Vendors Offering Products into the Space

Figure 3.28: Growth or Decline in Importance of the Various HCA Vendors to the End-User Community

Figure 3.29: Percentage of HCA Experiments that Involve GFP across the Market Landscape

Figure 3.30: Breakout of HCA Reagents Marketplace: Home-Brew Versus Off-the-Shelf

Figure 3.31: Breakout of Spending into the Various Components of the HCA Discipline

Figure 3.32: Forecast Growth of the Total Screening Space—Broken-out by Primary Screening, Secondary Screening (Includes HCA as a Subset) and ADME/Tox

Figure 3.33: Forecast Growth of the Screening Space—Broken-out by Cell-based Assays and Biochemical Assays

Figure 4.1: Drug Discovery and Development Ensemble and the Position of the Various Segments of HCA in the Space

Figure 4.2: Relative Size and Position of the HCA Space in the Overall Scheme of the Life Science Tools Marketplace

Figure 5.1: HCA: Positional Biosensors Using Caspases and Monitoring the Translocation of a Tagged Protein from the Cytoplasm to the Nucleus

Figure 6.1: Druggability of the Various Target Classes: Breakout of the Drug Targets Today into their Constituent Classes

Figure 6.2: GPCR Assay Technologies

LIST OF TABLES

Table 2.1: Comparison of the Key Features of HCA and HCS

Table 2.2: Impact of HCA on Drug Discovery—Several Drivers are Addressed

Table 2.3: Biological Application Areas Associated with HCA

Table 2.4: Classes of Measurements and Targets Identified Using Phenotypic Screening (HCA)

Table 2.5: Classes of Cellular Measurements Possible with Fluorescent Protein Biosensors

Table 2.6: Multi-Parameter HCA Assays to Study Biological Systems in Life Science Research and Drug Discovery—Demonstrates the Breadth and Scalability of the HCA Approach

Table 2.7: Companies Offering Systems for High-Throughput Imaging

Table 2.8: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA—I

Table 2.9: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA—II

Table 2.10: Price Points and Target Markets of the Various HCA Instrument Platforms

Table 2.11: Companies Offering Flow Cytometry Products and Services

Table 2.12: Integrated Product Platforms Offered by the Different HCA Vendors

Table 2.13: Biologies interrogated by Cellomics HCA Assays

Table 2.14: Cellomics HitKit® HCA Assay/Reagent Kits and the Therapeutic Areas Where They Find Application

Table 2.15: Assay/Reagent Portfolio of Millipore Addressing HCA Applications

Table 2.16: Cell Lines for GPCR HCA that can be Deployed onto the BD Biosciences/Atto Pathway HT™ Instrument Platform

Table 2.17: Examples of High Content Screens

Table 3.1: What Fraction of HCA Assays are Cell-based Versus Biochemical-based

Table 4.1: Comparison of the Key Features of HCA and HCS

Table 4.2: Snapshot of the Various HCA Assays Demonstrating the Scalability of this Discipline

Table 5.1: Modes of Digital Imaging

Table 5.2: Modes of Fluorescence

Table 5.3: Major HCA Instrumentation

Table 5.4: Image Analysis Algorithms

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.